Annual report [Section 13 and 15(d), not S-K Item 405]

Schedule of Segment Financial Information (Details)

v3.26.1
Schedule of Segment Financial Information (Details) - USD ($)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Revenue from External Customer [Line Items]    
Total research and development $ 2,929,983 $ 8,203,691
Total selling, general and administrative 4,843,615 4,309,551
Interest income 215,041 225,781
Net loss (7,558,557) (12,287,461)
Clinincal [Member]    
Revenue from External Customer [Line Items]    
Total research and development 705,645 5,796,196
Chemistry Manufacturing and Controls [Member]    
Revenue from External Customer [Line Items]    
Total research and development 349,645 454,913
Personnel Related [Member]    
Revenue from External Customer [Line Items]    
Total research and development 1,874,693 1,952,582
Total selling, general and administrative 1,481,404 1,719,364
Compliance [Member]    
Revenue from External Customer [Line Items]    
Total selling, general and administrative 2,623,871 2,590,187
Marketing Expense [Member]    
Revenue from External Customer [Line Items]    
Total selling, general and administrative $ 738,340